The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

BACKGROUND: First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side...

Descripción completa

Detalles Bibliográficos
Autores principales: Zandbergen, Ingrid M., Zamanipoor Najafabadi, Amir H., Pelsma, Iris C. M., van den Akker-van Marle, M. Elske, Bisschop, Peter H. L. T., Boogaarts, H. D. Jeroen, van Bon, Arianne C., Burhani, Bakhtyar, le Cessie, Saskia, Dekkers, Olaf M., Drent, Madeleine L., Feelders, Richard A., de Graaf, Johan P., Hoogmoed, J., Kapiteijn, Kitty K., van der Klauw, Melanie M., Nieuwlaat, Willy-Anne C. M., Pereira, Alberto M., Stades, Aline M. E., van de Ven, Annenienke C., Wakelkamp, Iris M. M. J., van Furth, Wouter R., Biermasz, Nienke R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465768/
https://www.ncbi.nlm.nih.gov/pubmed/34563236
http://dx.doi.org/10.1186/s13063-021-05604-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465768/
https://www.ncbi.nlm.nih.gov/pubmed/34563236
http://dx.doi.org/10.1186/s13063-021-05604-y

Ejemplares similares